Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Dasatinib vs Imatinib in newly diagnosed chronic phase CML
2006-005712-27Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Dasatinib arm with Imatinib arm (2 arms). Primary endpoint: Best confirmed complete cytogenetic response within 12 months. Started Jul 2007; status: completed.
02
Drugs
dasatinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2006-005712-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005712-27.